BI 771716
/ Boehringer Ingelheim, CDR-Life
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
October 03, 2025
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=188 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting
Enrollment closed • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
September 19, 2025
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2027 ➔ Oct 2026
Trial completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
July 09, 2025
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: Boehringer Ingelheim | Initiation date: May 2024 ➔ Jan 2025
Trial initiation date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
June 06, 2025
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: Boehringer Ingelheim | Initiation date: Jan 2025 ➔ May 2024
Trial initiation date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
February 25, 2025
CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy
(Businesswire)
- P1 | N=20 | NCT06006585 | Sponsor: Boehringer Ingelheim | "CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate for the treatment of geographic atrophy (GA), a leading cause of vision loss....This milestone follows successful Phase 1 results demonstrating a favorable safety profile for BI 771716 across both single and multiple intravitreal doses."
P1 data • Ophthalmology
January 10, 2025
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
December 09, 2024
VERDANT: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Boehringer Ingelheim
Metastases • New P2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
June 07, 2024
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed
Metastases • Trial completion • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
March 12, 2024
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=20 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting
Enrollment closed • Metastases • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
October 02, 2023
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
August 23, 2023
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Boehringer Ingelheim
Metastases • New P1 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders
1 to 11
Of
11
Go to page
1